{"title":"一项旨在改善塞内加尔新诊断的弥漫性大b细胞淋巴瘤患者诊断和治疗的试点合作研究：淋巴达克研究","authors":"Saliou Diop, Charline Moulin, Sokhna Aïssatou Touré, Serigne Mourtalla Gueye, Sabine Deltour, Yankhoba Diop, Fatou Samba Ndiaye, Mouhamadou Cherif Dial, Hervé Sartelet, Moussa Seck, Seynabou Fall, Alioune Badara Senghor, Awa Oumar Touré, Blaise Felix Faye, Elimane Seydi Bousso, Alioune Badara Diallo, Mohamed Keita, Elhadji Daouda Niang, Nata Dieng, Jean Vigneron, Catherine Thieblemont, Vincent Lévy, Martine Raphael, Pierre Feugier","doi":"10.1002/jha2.70133","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Management of diffuse large B-cell lymphoma (DLBCL) in Africa is hampered by limited access to diagnosis and treatment, due to the small number of haematopathologists and lack of clear healthcare pathway. A cooperation between France and Senegal was established to improve diagnosis and provide access to the standard-of-care (R-CHOP) to patients with DLBCL in Dakar.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Surgical biopsies were examined in Senegal, then through the Internet Pathology Suite platform, and, when needed, further studied in France. A diagnosis was thus reached for 65/70 biopsies from adults with suspected lymphoma, including 31 DLBCL. A total of 30 patients entered a pilot treatment of six cures of R-CHOP, follow-up and support therapy, between July 2018 and May 2022. The overall response rate was 73% with 57% of complete responses. With a median follow-up of 11.4 months, 24-month overall and progression-free survival rates are of 80% (95% CI 58–91) and 74% (95% CI 50–88). Grade 3/4 haematological toxicity was reported in 20% of the cases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study brings the proof-of-concept that an accurate DLBCL diagnosis can be obtained in Senegal with organized support and that R-CHOP therapy can be properly conducted, yielding the expected efficacy with acceptable safety.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>SEN18/11</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 4","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70133","citationCount":"0","resultStr":"{\"title\":\"A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK Study\",\"authors\":\"Saliou Diop, Charline Moulin, Sokhna Aïssatou Touré, Serigne Mourtalla Gueye, Sabine Deltour, Yankhoba Diop, Fatou Samba Ndiaye, Mouhamadou Cherif Dial, Hervé Sartelet, Moussa Seck, Seynabou Fall, Alioune Badara Senghor, Awa Oumar Touré, Blaise Felix Faye, Elimane Seydi Bousso, Alioune Badara Diallo, Mohamed Keita, Elhadji Daouda Niang, Nata Dieng, Jean Vigneron, Catherine Thieblemont, Vincent Lévy, Martine Raphael, Pierre Feugier\",\"doi\":\"10.1002/jha2.70133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Management of diffuse large B-cell lymphoma (DLBCL) in Africa is hampered by limited access to diagnosis and treatment, due to the small number of haematopathologists and lack of clear healthcare pathway. A cooperation between France and Senegal was established to improve diagnosis and provide access to the standard-of-care (R-CHOP) to patients with DLBCL in Dakar.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Surgical biopsies were examined in Senegal, then through the Internet Pathology Suite platform, and, when needed, further studied in France. A diagnosis was thus reached for 65/70 biopsies from adults with suspected lymphoma, including 31 DLBCL. A total of 30 patients entered a pilot treatment of six cures of R-CHOP, follow-up and support therapy, between July 2018 and May 2022. The overall response rate was 73% with 57% of complete responses. With a median follow-up of 11.4 months, 24-month overall and progression-free survival rates are of 80% (95% CI 58–91) and 74% (95% CI 50–88). Grade 3/4 haematological toxicity was reported in 20% of the cases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study brings the proof-of-concept that an accurate DLBCL diagnosis can be obtained in Senegal with organized support and that R-CHOP therapy can be properly conducted, yielding the expected efficacy with acceptable safety.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>SEN18/11</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 4\",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70133\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70133\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
非洲弥漫性大b细胞淋巴瘤（DLBCL）的治疗受到诊断和治疗渠道有限的阻碍，原因是血液病病理学家数量少，缺乏明确的医疗途径。法国和塞内加尔之间建立了一项合作，以改善达喀尔大淋巴细胞白血病患者的诊断并提供获得标准治疗（R-CHOP）的机会。结果在塞内加尔进行手术活检，然后通过互联网病理学套件平台进行检查，必要时在法国进行进一步研究。因此，70例疑似淋巴瘤的成人活检中有65例得到诊断，其中31例为DLBCL。在2018年7月至2022年5月期间，共有30名患者进入了6种R-CHOP的试点治疗，随访和支持治疗。总有效率为73%，完全有效率为57%。中位随访11.4个月，24个月的总生存率和无进展生存率分别为80% （95% CI 58-91）和74% （95% CI 50-88）。20%的病例报告3/4级血液学毒性。结论本研究证明了塞内加尔在有组织的支持下可以获得准确的DLBCL诊断，R-CHOP治疗可以正确进行，产生预期的疗效和可接受的安全性。试验注册SEN18/11
A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK Study
Introduction
Management of diffuse large B-cell lymphoma (DLBCL) in Africa is hampered by limited access to diagnosis and treatment, due to the small number of haematopathologists and lack of clear healthcare pathway. A cooperation between France and Senegal was established to improve diagnosis and provide access to the standard-of-care (R-CHOP) to patients with DLBCL in Dakar.
Results
Surgical biopsies were examined in Senegal, then through the Internet Pathology Suite platform, and, when needed, further studied in France. A diagnosis was thus reached for 65/70 biopsies from adults with suspected lymphoma, including 31 DLBCL. A total of 30 patients entered a pilot treatment of six cures of R-CHOP, follow-up and support therapy, between July 2018 and May 2022. The overall response rate was 73% with 57% of complete responses. With a median follow-up of 11.4 months, 24-month overall and progression-free survival rates are of 80% (95% CI 58–91) and 74% (95% CI 50–88). Grade 3/4 haematological toxicity was reported in 20% of the cases.
Conclusion
This study brings the proof-of-concept that an accurate DLBCL diagnosis can be obtained in Senegal with organized support and that R-CHOP therapy can be properly conducted, yielding the expected efficacy with acceptable safety.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
